Literature DB >> 18337622

Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma.

Yasuhisa Hasegawa1, Mitsuo Goto, Nobuhiro Hanai, Kei Ijichi, Akihiro Terada, Ikuo Hyodo, Tetsuya Ogawa, Masakazu Fukushima.   

Abstract

AIMS: The main purpose of the current study was to find predictive biomarkers that can be routinely used for the response to chemotherapy in head and neck squamous cell carcinoma (HNSCC).
METHODS: From this standpoint, we selected the histoculture drug response assay (HDRA) to assess in vitro chemosensitivity, and real-time reverse transcription polymerase chain reaction to investigate the gene expression profile of individual tumors as available predictive biomarkers. Using both surgery and biopsy specimens, we analyzed their gene expression profiles using the 18 markers that we thought were likely predictors of the response to anti-cancer agents.
RESULTS: Statistically significant associations were found between 5-fluorouracil (5-FU) sensitivity in HDRA and HER-2 mRNA expression level (p = 0.0030). Moreover, HER-2 expression was significantly associated with cisplatin sensitivity (p = 0.0089). Cisplatin sensitivity in HDRA was also demonstrated to have a significant association with epidermal growth factor receptor (EGFR) expression in which the group with cisplatin resistance tended to have a higher expression level than the sensitive group (p = 0.0385).
CONCLUSION: HER-2 and EGFR may be possible reliable predictive biomarkers for anti-cancer therapy, and might help in the decision-making process for individual patients with HNSCC. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18337622     DOI: 10.1159/000120998

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  6 in total

1.  Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.

Authors:  Yalei Zhang; Haihong Yang; Yuan Qiu; Qiuhua Deng; Jun Liu; Meiling Zhao; Ping He; Mingcong Mo; Xusen Zou; Jianxing He
Journal:  Med Oncol       Date:  2014-01-23       Impact factor: 3.064

2.  Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro.

Authors:  Sarah N Cross; Emiliano Cocco; Stefania Bellone; Valsamo K Anagnostou; Stacey L Brower; Christine E Richter; Eric R Siegel; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin
Journal:  Am J Obstet Gynecol       Date:  2010-04-24       Impact factor: 8.661

3.  Predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers.

Authors:  Yasuhisa Hasegawa; Mitsuo Goto; Nobuhiro Hanai; Taijiro Ozawa; Hitoshi Hirakawa
Journal:  Mol Clin Oncol       Date:  2017-11-29

Review 4.  ErbB receptors in the biology and pathology of the aerodigestive tract.

Authors:  Sarah Morgan; Jennifer R Grandis
Journal:  Exp Cell Res       Date:  2008-08-23       Impact factor: 3.905

Review 5.  Targeting EGFR resistance networks in head and neck cancer.

Authors:  Vladimir Ratushny; Igor Astsaturov; Barbara A Burtness; Erica A Golemis; Joshua S Silverman
Journal:  Cell Signal       Date:  2009-03-01       Impact factor: 4.315

Review 6.  Ex Vivo Culture Models to Indicate Therapy Response in Head and Neck Squamous Cell Carcinoma.

Authors:  Imke Demers; Johan Donkers; Bernd Kremer; Ernst Jan Speel
Journal:  Cells       Date:  2020-11-23       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.